Previous 10 | Next 10 |
home / stock / gnmsf / gnmsf news
Genmab A/S (GMAB) Q2 2021 Results Conference Call August 11, 2021 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Tahi Ahmadi - Chief Medical Officer Conference Call Participants Wim...
The following slide deck was published by Genmab A/S in conjunction with their 2021 Q2 earnings call. For further details see: Genmab A/S 2021 Q2 - Results - Earnings Call Presentation
Genmab A/S (NASDAQ:GMAB): Q2 GAAP EPS of DKK4.64. Revenue of DKK1.97B (-63.9% Y/Y). Press Release The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application, for patients with recurrent or metastatic cervical cancer. DARZALEX net sales increas...
BMEZ is a fund focused on the growth side of healthcare, with exposure to some private investments. Private investments can be quite lucrative as it is participating before public launches that can see shares rise spectacularly. On the other side of this large potential is a highe...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA And Healthcare Dashboard For July
Genmab A/S (GMAB) Q1 2021 Earnings Conference Call May 05, 2021 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Wimal Kapadia - Bernstein Michael Schmidt - Guggenheim...
Genmab A/S (GNMSF) and Seagen (SGEN) announces that the U.S. FDA has accepted for Priority Review the Biologics License Application ((BLA)) seeking accelerated approval for tisotumab vedotin.This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recur...
The fund just received a huge distribution boost, making it more appealing to income-oriented investors. The latest declines in BMEZ also coincide with an attractive discount on the fund. BMEZ is an attractive long-term option in the healthcare space that focuses on new tech - tho...
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q4 earnings call. For further details see: Genmab A/S 2020 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...